The vaccine approved for emergency authorization is manufactured by pharmaceutical company Novavax, with updated vaccines from ... the most current COVID-19 variant. “It’s not bivalent, which is the ...

mRNA-1083 consists of components of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, its next-generation bivalent ... mRNA – and Sanofi/Novavax, which are working ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold. The Gaithersburg, Md., vaccine developer said Monday that the U.S ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported ...

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...